Inozyme Pharma Inc (NASDAQ: INZY)’s stock price has soared by 19.63 in relation to previous closing price of 3.26. Nevertheless, the company has seen a gain of 36.36% in its stock price over the last five trading days. GlobeNewsWire reported 2023-11-09 that BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences:
Is It Worth Investing in Inozyme Pharma Inc (NASDAQ: INZY) Right Now?
, and the 36-month beta value for INZY is at 1.13. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for INZY is $21.00, which is $17.1 above the current market price. The public float for INZY is 42.39M, and currently, shorts hold a 4.90% of that float. The average trading volume for INZY on November 21, 2023 was 544.83K shares.
INZY’s Market Performance
The stock of Inozyme Pharma Inc (INZY) has seen a 36.36% increase in the past week, with a 35.42% rise in the past month, and a -19.42% fall in the past quarter. The volatility ratio for the week is 9.32%, and the volatility levels for the past 30 days are at 8.00% for INZY. The simple moving average for the past 20 days is 29.91% for INZY’s stock, with a -15.38% simple moving average for the past 200 days.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Jefferies repeating the rating for INZY by listing it as a “Buy.” The predicted price for INZY in the upcoming period, according to Jefferies is $6 based on the research report published on March 23, 2023 of the current year 2023.
INZY Trading at 8.81% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.79% of loss for the given period.
Volatility was left at 8.00%, however, over the last 30 days, the volatility rate increased by 9.32%, as shares surge +32.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.24% lower at present.
During the last 5 trading sessions, INZY rose by +36.36%, which changed the moving average for the period of 200-days by +36.36% in comparison to the 20-day moving average, which settled at $3.05. In addition, Inozyme Pharma Inc saw 271.43% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at INZY starting from Hopfner Robert Lorne, who purchase 833,333 shares at the price of $4.80 back on Aug 01. After this action, Hopfner Robert Lorne now owns 2,923,110 shares of Inozyme Pharma Inc, valued at $3,999,998 using the latest closing price.
Pivotal bioVenture Partners Fu, the Director of Inozyme Pharma Inc, purchase 833,333 shares at $4.80 during a trade that took place back on Aug 01, which means that Pivotal bioVenture Partners Fu is holding 2,923,110 shares at $3,999,998 based on the most recent closing price.
Stock Fundamentals for INZY
The total capital return value is set at -57.76, while invested capital returns managed to touch -56.77. Equity return is now at value -46.22, with -37.90 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 5.72 points at debt to equity in total, while total debt to capital is 5.41. Total debt to assets is 4.87, with long-term debt to equity ratio resting at 5.04. Finally, the long-term debt to capital ratio is 4.76.
The liquidity ratio also appears to be rather interesting for investors as it stands at 8.93.
In conclusion, Inozyme Pharma Inc (INZY) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.